Randomized trial · people

Tirzepatide: 62% MASH resolution in 15 mg arm vs 10% on placebo

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In people with MASH and moderate or severe fibrosis, 52 weeks of tirzepatide led to MASH resolution without worse fibrosis more often than placebo in this phase 2 trial.

Kind
Randomized trial
Studied in
People
Number studied
190
Published
2024
Journal
N Engl J Med

What they tested

The team tested whether once-weekly tirzepatide could resolve MASH, a progressive liver disease, without worsening fibrosis (scarring) in people with moderate or severe fibrosis.

How the study was done

A phase 2, double-blind, randomized, placebo-controlled trial at many centers in 190 participants with biopsy-confirmed MASH and stage F2 or F3 fibrosis. Each person got a weekly shot of tirzepatide (5 mg, 10 mg or 15 mg arm) or placebo, a dummy shot, for 52 weeks.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking tirzepatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

At 52 weeks, MASH resolved without worse fibrosis in 10% on placebo, 44% in the 5 mg arm, 56% in the 10 mg arm and 62% in the 15 mg arm (P<0.001 for each). Fibrosis improved by at least one stage without worse MASH in 30% on placebo, 55% in the 5 mg arm and 51% in both the 10 mg and 15 mg arms. The most common side effects with tirzepatide were gut-related, and most were mild or moderate.

What it doesn’t show

This was a 52-week phase 2 trial, and only 157 of the 190 people had a week 52 liver biopsy that could be scored, so missing results were filled in using the placebo group's pattern. It was funded by Eli Lilly, and the authors say larger and longer trials are needed.

The paper

Loomba et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. N Engl J Med. 2024.

The compound

More studies on Tirzepatide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking tirzepatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo